Virtu Financial’s Celldex Therapeutics CLDX Stock Holding History

Virtu Financial’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,830	Closed	-$629K	–	1679
2026 Q1	$629K	Buy	+19,830	New	+$541K	0.03%	490
2024 Q2	–	Sell	-19,644	Closed	-$824K	–	1381
2024 Q1	$824K	Buy	+19,644	New	+$807K	0.06%	271
2019 Q4	–	Sell	-13,993	Closed	-$30K	–	1481
2019 Q3	$30K	Buy	+13,993	New	+$32.4K	﹤0.01%	1252
2019 Q2	–	Sell	-25,826	Closed	-$127K	–	1494
2019 Q1	$127K	Buy	25,826 +24,826	+2,483%	+$131K	0.01%	1091
2018 Q4	$3K	Sell	1,000 -420	-30%	-$2.06K	﹤0.01%	1495
2018 Q3	$10K	Sell	1,420 -164	-10%	-$1.15K	﹤0.01%	1448
2018 Q2	$12K	Buy	1,584 +816	+106%	+$10.9K	﹤0.01%	1895
2018 Q1	$27K	Buy	+768	New	+$29.8K	﹤0.01%	1794
2017 Q4	–	Sell	-2,332	Closed	-$100K	–	2417
2017 Q3	$100K	Buy	+2,332	New	+$87.4K	0.01%	2076
2015 Q3	–	Sell	-801	Closed	-$303K	–	324
2015 Q2	$303K	Buy	+801	New	+$318K	0.03%	258

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial's CLDX Position: Q2 2026 in Review

Virtu Financial sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 19,830 shares — an estimated $629K sold.

Virtu Financial first reported a position in CLDX in Q2 2015 and held it in 10 quarters. The position peaked at $824K in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Virtu Financial reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 19,830 Celldex Therapeutics shares in Q2 2026, an estimated $629K.
Virtu Financial first reported a position in Celldex Therapeutics in Q2 2015 and held it in 10 quarters.
Virtu Financial's Celldex Therapeutics position peaked at $824K in Q1 2024.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.